Incyte knocking on the door of a new upward trend after today’s 6% pop
Reports of results from the December 1-4 meeting of the American Society of Hematology continue to move biotech stocks. Today it was Incyte's (INCY) turn. The company announced positive results for a Phase 2 trial evaluating Incyte's Jakafi in combination with...Incyte news continues to rebuild credibility of pipeline
Shares of Incyte  (INCY) climbed 2.51% today on the announcement of positive results from a Phase 2 clinical trial, GEOMETRY mono-1, evaluating MET inhibitor capmatinib in 94 adult patients with advanced non-small cell lung cancer. The company presented the data at...Selling Incyte calls at $95 now to re-buy after weekend at lower strike
Shares of Incyte (INCY), a member of my Jubak Picks portfolio, have been marching steadily higher in the last couple of weeks. The stock is 19.6% higher since the $61.75 low on August 6. And it's up another 2.06% today, Tuesday, August 28. But the call options I own...Incyte beats on revenue, misses on earnings; reports good progress in pipeline
I am on vacation until August 26. I am using that downtime to catch up on some of the earnings reports I missed during the very busy second quarter earnings season. On July 30 Incyte (INCY) reported second quarter earnings of 26 cents a share, 4 cents below the Wall...FDA delivers less than half a loaf to INCY and LLY in approving Olumiant
Today the U.S. Food & Drug Administration did finally approve Baricitinib, now known as Olumiant, for the treatment of moderately-to-severely active rheumatoid arthritis. But the approval carries more restrictions than expected. The FDA approved only the 2...Here’s what’s behind the plunge in biotech–and in Incyte and Nektar
I’m sure you’ve noticed. As bad as the losses in the general market have been on some recent days–such as yesterday–the punishment meted out to biotech stocks has been worse.Part of that has been the “usual” pattern in a market that is busy selling “risk.” Biotech stocks always get hit hard in such a period. But there’s more, much more going on that’s specific to the sector. And in fact specific to Merck (MRK) and Incyte (INCY), a biotech that’s in my Jubak Picks Portfolio and where I also hold options in my Volatility Portfolio. The key event here for the sector is the April 5 news that Merck and Incyte were pulling the plug on a clinical trial
FDA sets next date for Incyte arthritis drug, baricitinib
The Food and Drug Administration today announced that its Arthritis Advisory Committee will meet on April 23 to discuss the application by Incyte (INCY) and Eli Lilly (LLY) for approval of baricitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis